Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 79

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Inaticabtagene Autoleucel in Children with Relapsed/Refractory (R/R) B-cell Acute Lymphoblastic Leukemia in China

Shiyuan Wang, Xiaoming Liu, Yongjun Fang, Kailin Xu, Hongsheng Zhou, Fei Li, Xianmin Guan, Yingyi He, Yi Feng, Lulu Lyu, Qunhui Peng, Xiaofan Zhu, Jianxiang Wang

Blood (2024) 144 (Supplement 1): 7200.

https://doi.org/10.1182/blood-2024-201125

Published: 2024

Journal Articles

Tucidinostat Plus Pediatric-Inspired Chemotherapy As First-Line Therapy for Newly Diagnosed ETP-ALL/Lbl: An Open-Label, Single-Arm, Phase 2 Trial

Jieping Lin, Chenhao Ding, Zicong Huang, Cai Zihong, Jia Li, Zhixiang Wang, Xiaofang Li, Xuan Zhou, Bailin He, Wenhao Zhong, Li Xuan, Qifa Liu, Yang Xu, Hongsheng Zhou

Blood (2024) 144 (Supplement 1): 839.

https://doi.org/10.1182/blood-2024-200513

Published: 2024

Journal Articles

ABC Regimen: Combination of 3rd Generation TKI Olverembatinib, Blinatumomab and Chidamide for Older New Diagnosed Ph-Positive ALL Patients

Junjie Chen, Hongsheng Zhou, Qifa Liu

Blood (2024) 144 (Supplement 1): 5881.

https://doi.org/10.1182/blood-2024-200685

Published: 2024

Journal Articles

BEAT Chemofree Regimen for Relapsed/Refractory and De Novo T-ALL

Jieping Lin, Xuan Zhou, Zhixiang Wang, Dainan Lin, Yu Zhan, Zan Li, Jiwei Huang, Yonghua Li, Xudong Ma, Qifa Liu, Li Xuan, Yang Xu, Hongsheng Zhou

Blood (2024) 144 (Supplement 1): 5901.

https://doi.org/10.1182/blood-2024-203250

Published: 2024

Journal Articles

Sustained Remission and Decreased Severity of CAR T-Cell Related Adverse Events: An Updated Report on the Pivotal Study of Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (r/r B-Cell ALL) in China

Blood (2024) 144 (Supplement 1): 4196.

https://doi.org/10.1182/blood-2024-199983

Published: 2024

Journal Articles

Evaluating the Effectiveness and Security of Antifungal Prophylaxis in Acute Lymphoblastic Leukemia Induction Chemotherapy

Yang Zhou, Hongsheng Zhou, Qifa Liu

Blood (2024) 144 (Supplement 1): 4191.

https://doi.org/10.1182/blood-2024-201468

Published: 2024

Journal Articles

IKZF1 Deletion Confers Resistance to CAR19 in r/r B-ALL Via CD19 Intron Retention

Cai Zihong, Baiwei Luo, Bailin He, Li Xuan, Qifa Liu, Hongsheng Zhou

Blood (2024) 144 (Supplement 1): 3412.

https://doi.org/10.1182/blood-2024-203362

Published: 2024

Journal Articles

Prognostic Impact of TP53 Mutation in Adult Acute Lymphoblastic Leukemia Treated with Pediatric-Inspired Regimen

Jiawang Ou, Xiuli Xu, Ya Zhou, Qifa Liu, Hongsheng Zhou

Blood (2023) 142 (Supplement 1): 6066.

https://doi.org/10.1182/blood-2023-186286

Published: 2023

Journal Articles

Treatment of Acute Lymphoblastic Leukemia with PDT Regimen Improves the Prognosis of Newly Diagnosed Central Nervous System Leukemia

Haimei Liang, Qifa Liu, Hongsheng Zhou

Blood (2023) 142 (Supplement 1): 5899.

https://doi.org/10.1182/blood-2023-188418

Published: 2023

Journal Articles

CRM1/XPO1-FOXO1 Pathway Is Associated with Clinical Outcome and Represents a Promising Target in B-Cell Acute Lymphocytic Leukemia

Shiyu Deng, Jiawang Ou, Cai Zihong, Zicong Huang, Jia Li, Qifa Liu, Hongsheng Zhou

Blood (2023) 142 (Supplement 1): 4253.

https://doi.org/10.1182/blood-2023-188459

Published: 2023

Journal Articles

Evaluation of the Effectiveness of Antifungal Prophylaxis in Adult Acute Lymphoblastic Leukemia during Induction Chemotherapy

Yang Zhou, Junjie Chen, Cai Zihong, Qifa Liu, Hongsheng Zhou

Blood (2023) 142 (Supplement 1): 4241.

https://doi.org/10.1182/blood-2023-188442

Published: 2023

Journal Articles

Allo-HSCT Improved Outcome of High Risk ALL in Pediatric-Inspired PDT-ALL-2016 Cohort

Junjie Chen, Zhixiang Wang, Qifa Liu, Hongsheng Zhou

Blood (2023) 142 (Supplement 1): 2229.

https://doi.org/10.1182/blood-2023-185940

Published: 2023

Journal Articles

Frontline Combination of 3 rd Generation TKI Olverembatinib and Blinatumomab for Ph+/Ph-like ALL Patients

Ting Zhang, Kaibo Zhu, Cai Zihong, Ren Lin, Qifa Liu, Hongsheng Zhou

Blood (2023) 142 (Supplement 1): 1504.

https://doi.org/10.1182/blood-2023-186139

Published: 2023

Journal Articles

The Pediatric-Inspired Regimen Improved Quality and Quantity of Life for Patients with Acute Lymphoblastic Leukemia，Beyond Age, Risk Stratification, and Hematopoietic Stem Cell Transplantation

Junjie Chen, Zhixiang Wang, Qifa Liu, Hongsheng Zhou

Blood (2023) 142 (Supplement 1): 1466.

https://doi.org/10.1182/blood-2023-188479

Published: 2023

Journal Articles

Olverembatinib(HQP1351)-Based Therapy in Adults with Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Advanced Chronic Myeloid Leukemia: Results of the Real-Life Study

Ziyu Wen, Zhiping Fan, Qiang Wang, Xuan Zhou, Zherou He, Zicheng Gao, Hong Chen, Hanyin Liang, Dongmei Luo, Xiaoli Liu, Hongsheng Zhou, Qifa Liu, Na Xu

Blood (2023) 142 (Supplement 1): 4538.

https://doi.org/10.1182/blood-2023-181850

Published: 2023

Journal Articles

CD19-Specific CAR NK Cells Coexpressing IL-21 Exhibit Superior Expansion and Antitumor Activity Against CD19-Postive Lymphoma

Bailin He, Hong Chen, Shikai Deng, Chengyao Li, Na Xu, Xiaoli Liu, Hongsheng Zhou, Qifa Liu

Blood (2023) 142 (Supplement 1): 6824.

https://doi.org/10.1182/blood-2023-178289

Published: 2023

Journal Articles

Efficacy and Safety of TLR2 Co-Stimulated CAR T Cells in CD19-Positive Lymphoid Malignancies with Central Nervous System Involvement

Bailin He, Hongsheng Zhou, Ren Lin, Zhixiang Wang, Na Xu, Qiang Wang, Jing Sun, Xiaoli Liu, Peng Li, Qifa Liu

Blood (2023) 142 (Supplement 1): 3484.

https://doi.org/10.1182/blood-2023-184492

Published: 2023

Journal Articles

Maintenance Therapy with Chidamide Decreases the Relapse in Fusion Gene-Positive AML Patients with MRD-Positive or ELN-High Risk

Guopan Yu, Zhao Yin, Jixian Huang, Huiqing He, Xuejie Jiang, Hongsheng Zhou, Pengcheng Huang, Yu Zhang

Blood (2023) 142 (Supplement 1): 5862.

https://doi.org/10.1182/blood-2023-182621

Published: 2023

Journal Articles

Venetoclax in Combination with Homoharringtonine and Cytarabine in the Treatment of Relapsed/Refractory Early T-Cell Precursor Acute Lymphoblastic Leukaemia: A Single Arm, Multicenter, Prospective, Phase II, Pilot Trial

Wenjuan Yu, Hongsheng Zhou, Lijing Shen, Dong Chen, Xiang Zhang, Yanan Zhu, Xin Huang, Ying Lu, Jian Hou, Qifa Liu, Jie Jin

Blood (2022) 140 (Supplement 1): 3260–3261.

https://doi.org/10.1182/blood-2022-164933

Published: 2022

Journal Articles

Chemotherapy or Hematopoietic Stem Cell Transplantation in B-Lineage Acute Lymphoblastic Leukemia Patients Based on IKZF1 and MRD Status

Shiyu Deng, Jiawang Ou, Zicong Huang, Cai Zihong, Bingqing Tang, Xiuli Xu, Yiqian Liu, Zhengwei Wu, Qifa Liu, Hongsheng Zhou

Blood (2022) 140 (Supplement 1): 11856.

https://doi.org/10.1182/blood-2022-166780

Published: 2022

NARROW

Efficacy and Safety of Inaticabtagene Autoleucel in Children with Relapsed/Refractory (R/R) B-cell Acute Lymphoblastic Leukemia in China

Tucidinostat Plus Pediatric-Inspired Chemotherapy As First-Line Therapy for Newly Diagnosed ETP-ALL/Lbl: An Open-Label, Single-Arm, Phase 2 Trial

ABC Regimen: Combination of 3rd Generation TKI Olverembatinib, Blinatumomab and Chidamide for Older New Diagnosed Ph-Positive ALL Patients

BEAT Chemofree Regimen for Relapsed/Refractory and De Novo T-ALL

Sustained Remission and Decreased Severity of CAR T-Cell Related Adverse Events: An Updated Report on the Pivotal Study of Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (r/r B-Cell ALL) in China

Evaluating the Effectiveness and Security of Antifungal Prophylaxis in Acute Lymphoblastic Leukemia Induction Chemotherapy

IKZF1 Deletion Confers Resistance to CAR19 in r/r B-ALL Via CD19 Intron Retention

Prognostic Impact of TP53 Mutation in Adult Acute Lymphoblastic Leukemia Treated with Pediatric-Inspired Regimen

Treatment of Acute Lymphoblastic Leukemia with PDT Regimen Improves the Prognosis of Newly Diagnosed Central Nervous System Leukemia

CRM1/XPO1-FOXO1 Pathway Is Associated with Clinical Outcome and Represents a Promising Target in B-Cell Acute Lymphocytic Leukemia

Evaluation of the Effectiveness of Antifungal Prophylaxis in Adult Acute Lymphoblastic Leukemia during Induction Chemotherapy

Allo-HSCT Improved Outcome of High Risk ALL in Pediatric-Inspired PDT-ALL-2016 Cohort

Frontline Combination of 3 rd Generation TKI Olverembatinib and Blinatumomab for Ph+/Ph-like ALL Patients

The Pediatric-Inspired Regimen Improved Quality and Quantity of Life for Patients with Acute Lymphoblastic Leukemia，Beyond Age, Risk Stratification, and Hematopoietic Stem Cell Transplantation

Olverembatinib(HQP1351)-Based Therapy in Adults with Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Advanced Chronic Myeloid Leukemia: Results of the Real-Life Study

CD19-Specific CAR NK Cells Coexpressing IL-21 Exhibit Superior Expansion and Antitumor Activity Against CD19-Postive Lymphoma

Efficacy and Safety of TLR2 Co-Stimulated CAR T Cells in CD19-Positive Lymphoid Malignancies with Central Nervous System Involvement

Maintenance Therapy with Chidamide Decreases the Relapse in Fusion Gene-Positive AML Patients with MRD-Positive or ELN-High Risk

Venetoclax in Combination with Homoharringtonine and Cytarabine in the Treatment of Relapsed/Refractory Early T-Cell Precursor Acute Lymphoblastic Leukaemia: A Single Arm, Multicenter, Prospective, Phase II, Pilot Trial

Chemotherapy or Hematopoietic Stem Cell Transplantation in B-Lineage Acute Lymphoblastic Leukemia Patients Based on IKZF1 and MRD Status

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only